Core Viewpoint - Synthetic biology and biomanufacturing are gaining significant attention and support from various sectors, including government, academia, and industry, highlighting their potential as new productive forces in the economy [1][15]. Group 1: Event Overview - The SynBio China Third China Synthetic Biology "Scientists + Entrepreneurs + Investors" Expo will be held on August 1-2, 2025, at the Suzhou International Expo Center [3]. - The expo will feature seven sub-conferences, including discussions on synthetic biology applications in food health, protein biomanufacturing, and innovative skincare [3][4]. Group 2: Industry Trends - Synthetic biology is seen as a key to understanding life and a disruptive technology that can accelerate China's transition from a large to a strong biological economy [15]. - The industry faces challenges such as achieving large-scale production, realizing the value of synthetic biological products, and innovating core competitiveness [15]. Group 3: Applications and Innovations - Innovations driven by synthetic biology include the development of next-generation food additives, personalized health foods, and sustainable protein sources [9][12]. - The application of synthetic biology in cosmetics is also notable, with advancements in recombinant collagen and bioactive ingredients for skincare [13][16]. Group 4: Collaboration and Networking - The event aims to facilitate collaboration among innovators, industry experts, and investors, providing a platform for project promotion and industry guidance [18]. - Various types of projects are encouraged to participate, including startups and application-oriented enterprises in synthetic biology [22].

湖北首鼎创始人桑涛博士是武汉东湖高新区首批产业领军人才，在武汉国家生物产业基地设立研发中心，在全球率先探 索建立以芦苇及农作物秸秆为原料的合成生物制造产业，生产生物树脂、生物塑料等先进环保新材料，获得50多项发明 专利。 湖北首鼎还从芦苇中提取高活性酶解木质素合成生物树脂，用于制造碳纤维复合材料，可应用于航空航天、轨道交通、 新能源等高端制造领域。目前全球碳纤维复合材料需求迅速增长，国产环氧树脂韧性不足，很多高端产品都从国外进 口。该公司研发的生物树脂可解决"卡脖子"问题，具有强大市场竞争力，得到行业高度认可。 日前从湖北首鼎实业有限公司获悉，全球首条以芦苇为原料的可降解生物塑料生产线在石首投产。这项自主研发的生产 技术国际领先，填补了非粮生物塑料制造领域的空白。 负责技术研发的上海汉禾生物新材料科技有限公司工程师刘畅介绍，传统塑料生产以石油为原料，不能降解，造成环境 污染，甚至危害人类健康；可降解生物塑料以玉米等粮食淀粉为原料，成本高，产品贵，应用受到限制。上海汉禾控股 的湖北首鼎生产的秸秆生物塑料，售价比粮食塑料显著降低，规模化生产后将比石化塑料价格更便宜，可完全降解为二 氧化碳和水，能有效解决白色污染难 ...

Core Viewpoint - The company plans to invest 320 million yuan in an "AI-driven precision fermentation and protein engineering shared demonstration project" to maintain its industry leadership and meet market demand for high-quality, low-cost products [1][2]. Investment Details - The company signed an investment agreement worth 390 million yuan with the Anhui Changfeng (Shuangfeng) Economic Development Zone Management Committee for the construction of an AI-driven bio-manufacturing R&D and pilot demonstration base [1]. - The total investment agreements signed with the Anhui Changfeng (Shuangfeng) Economic Development Zone in the past 12 months amount to 710 million yuan, meeting the disclosure standards of the Sci-Tech Innovation Board [1]. Project Specifications - The project will include the construction of new production workshops, finished product warehouses, tank areas, office buildings, R&D buildings, and comprehensive buildings, with an estimated construction period of 36 months [2]. - Funding for the project will come from the company's own or self-raised funds [2]. Company Overview - The company focuses on synthetic biology technology and is engaged in the R&D, production, and sales of bio-based products, including amino acids, vitamins, and bio-based new material monomers [2]. - In 2024, the company achieved a revenue of 2.178 billion yuan, a year-on-year increase of 12.37%, and a net profit of 190 million yuan [2]. Technological Advancements - The company utilizes gene synthesis, gene editing, pathway assembly and optimization, and global cell optimization technologies to create new cell factories, accelerating the industrialization of scientific achievements [3]. - The development of AI technology is expected to enhance gene editing efficiency, metabolic pathway optimization, production process optimization, and protein design, further empowering breakthroughs in biosynthesis technology [3][4]. Production Innovation - The company aims to adopt advanced microbial fermentation technology combined with AI for precise control of the fermentation process, introducing automation equipment and control systems for real-time monitoring and optimization of production [4]. - The investment will help the company build an intelligent production system, enhancing its core competitiveness [4].

Core Viewpoint - Anhui Huaheng Biological Technology Co., Ltd. plans to invest RMB 320 million in the construction of an "Artificial Intelligence Precision Fermentation and Protein Engineering Shared Demonstration Project" to maintain its industry leadership and meet market demand for high-quality, low-cost products [1][2]. Investment Overview - The investment amount for the project is RMB 320 million, primarily funded by self-owned or self-raised funds, with a construction period of 36 months [1][2]. - The project is located in the northeast corner of the intersection of Shuangfeng Road and Yingzhou Road in the Shuangfeng Economic Development Zone, Changfeng County [1]. Decision and Approval Process - The investment decision was approved by the company's management and does not require board approval, as it falls within the management's authority [1][2]. - The company has signed a total of RMB 710 million in investment agreements with the Changfeng (Shuangfeng) Economic Development Zone Management Committee over the past 12 months [2]. Project Details - The project aims to utilize advanced microbial fermentation technology combined with artificial intelligence for precise control of the fermentation process, enhancing production efficiency and product quality [5]. - The project will establish a smart production system, improving the company's core competitiveness in the market [5]. Environmental and Safety Compliance - The company is required to adhere to national environmental protection standards and energy-saving regulations during the construction and operation of the project [4]. - The project must comply with safety management laws and regulations, ensuring proper handling of wastewater, waste gas, and solid waste [4].

融行业智慧、共襄盛举 作为新质生产力的代表，合成生物学、生物制造以及生物产业，近些年，受到来自政产学研用金 各方广泛关注和重点支持，多地政府将合成生物制造产业写进工作报告。 科学家、企业家和投 资家，在产业发展中发挥着重要作用。 聚产业力量、擘画未来 SynBio China第三届中国合成生物学"科学家+企业家+投资家"博览会 将于2025年8月1-2日在 苏州国际博览中心B馆 举办（同期举办 第七届CMC-China博览会 ）！ 本次博览会共包含7个子会议： 展会名称： Synbio China 第三届中国合成生物学"科学家+企业家+投资家"博览会 第三届中国合成生物学"科学家+企业家+投资家"大会 SynBio China合成生物学与食品大健康产业大会 中国蛋白生物制造大会 美之原·合成生物学功能护肤大会 美之注·注射医疗美容产业大会 SynBio China合成生物学产学研对接会 SynBio China合成生物学新锐项目路演 诚邀莅临，共襄盛举 展会 时间： 2025年8月1-2日 展会 地点： 苏州国际博览中心·B馆 展会 规模： 20000+ 主办单位： synbio深波 支持单位： Synbio ...

2025.05. 19 本文字数：2378，阅读时长大约4分钟 作者 | 第一财经 祝嫣然 2025年是国有企业改革深化提升行动的收官之年，也是新一轮改革的谋划之年。 国务院国资委全面深化改革领导小组日前召开2025年第一次全体会议，听取高质量完成国有企业改 革深化提升行动重点难点任务落实情况，研究进一步深化国资国企改革的方案。 会议明确，要高起点谋划好下一步深化国资国企改革工作，突出解决制约国有企业高质量发展的深层 次体制机制难题，构建与新质生产力更相适应的生产关系，推动国有资本和国有企业做强做优做大， 增强核心功能、提升核心竞争力，更好履行战略使命。 更大力度推进产业焕新 2023年启动实施的国企改革深化提升行动取得积极进展。会议指出，功能使命类任务加快落地，关 键核心技术攻关实现新突破，产业焕新行动、未来产业启航行动深入实施，传统产业转型升级持续加 速，重点领域重组整合扎实推进，"三个作用"充分发挥。 此外，体制机制类任务巩固深化，中国特色现代企业制度进一步完善，三项制度改革深入推进，"一 业一策、一企一策"考核全面实施，穿透式监管进一步强化，监管效能明显提高，有效激发企业内生 活力动力。 去年中央企业 ...

Core Viewpoint - The biomanufacturing industry is emerging as a new engine for economic growth, with a significant focus on the new protein sector as a key area for development [1][2]. Group 1: New Protein Manufacturing Center - The National Investment Group and Wuxi City have established the National Investment New Protein Biomanufacturing Innovation Center to address bottlenecks in new protein research and industrialization [2][4]. - The center aims to accelerate the development and cost optimization of various new protein products, covering fields such as food, nutrition, healthcare, and materials [2][4]. Group 2: Challenges and Opportunities - New protein is defined as edible protein not reliant on traditional livestock or fishery methods, utilizing innovative technologies like microbial fermentation and synthetic biology [4]. - China faces a significant protein gap, with 2024 grain imports projected to exceed 158 million tons, including 105 million tons of soybeans, which are primarily used for animal feed [5]. - The shortage of edible protein has become a safety issue, prompting the government to promote comprehensive food resource development [5]. Group 3: Investment and Development Strategy - Since 2020, the new protein industry in China has shown strong growth, although the capital market's downturn in 2023 has posed challenges [5][6]. - The National Investment Group has established the National Investment Biomanufacturing Innovation Research Institute with a registered capital of 6 billion yuan, marking a significant step in supporting the biomanufacturing industry [5][6]. - The group aims to achieve a total output value of 60 billion yuan in the biomanufacturing sector by the end of the 14th Five-Year Plan [6]. Group 4: Financial Support and Collaboration - The National Investment Group manages funds exceeding 270 billion yuan, having invested over 4 billion yuan in 25 biomanufacturing companies [6][7]. - The group has partnered with various local governments to establish industry guidance funds, including a 2 billion yuan biomanufacturing venture capital fund in Tianjin [6][7]. - Future plans include collaborating with private capital to explore differentiated management of mixed-ownership enterprises, enhancing the vitality and competitiveness of the industry [7].

Group 1 - The core viewpoint emphasizes the need for central enterprises to accelerate the development of new productive forces and cultivate strategic emerging industries with core competitiveness [1][2] - The 2025 deadline marks the conclusion of the current round of state-owned enterprise reform, focusing on deepening reforms and addressing systemic issues that hinder high-quality development [1][2] - The State-owned Assets Supervision and Administration Commission (SASAC) has initiated actions to enhance the quality of state-owned enterprises, including the "Industry Renewal Action" and "Future Industry Launch Action" [2][4] Group 2 - In 2022, central enterprises invested 2.7 trillion yuan in strategic emerging industries, a year-on-year increase of 21.8%, with the proportion of total investment exceeding 40% for the first time [4] - The SASAC aims to strengthen the organization and ensure high-quality completion of the reform actions, focusing on resource allocation to strategic emerging industries [2][4] - The SASAC is also enhancing regulatory efficiency through a smart, penetrating regulatory system to monitor financial resources and improve operational efficiency [6][7] Group 3 - The focus on new technologies and industries, such as artificial intelligence and quantum information, is accelerating, with significant advancements like the launch of a distributed cryptographic system by China Telecom [5] - The SASAC is promoting a modern enterprise system and deepening reforms to enhance the competitiveness of state-owned enterprises in strategic emerging industries [2][3]

Core Insights - The National Investment Group (国投) is establishing a dedicated CVC fund for the biomanufacturing industry, focusing on early-stage, small investments in hard technology to support strategic emerging industries and core technology breakthroughs [1][3] - The biomanufacturing industry is recognized as a new engine for economic growth, with the establishment of the National Investment Group's new protein biomanufacturing innovation center aimed at addressing bottlenecks in new protein research and industrialization [1][2] Group 1: Industry Development - The new protein, which does not rely on traditional livestock or fishery methods, is synthesized using innovative technologies like microbial fermentation, addressing the significant protein gap in China, where over 66% of grain imports are soybeans [2] - The shortage of edible protein has become a safety issue, prompting the government to promote a comprehensive approach to food resource development [2] Group 2: Investment and Funding - The National Investment Group has invested in 25 biomanufacturing companies, totaling over 4 billion yuan, and has established various government-guided funds to support the industry [4] - The National Investment Group's funds exceed 270 billion yuan, with investments in 424 specialized enterprises, supporting 120 companies to go public, which constitutes 10% of the total on the Science and Technology Innovation Board [3][4] Group 3: Strategic Initiatives - The establishment of the National Investment Group's Biomanufacturing Innovation Research Institute, with a registered capital of 6 billion yuan, marks a strategic initiative to cultivate the biomanufacturing industry [3] - The National Investment Group aims to achieve a total output value of 60 billion yuan in the biomanufacturing sector by the end of the 14th Five-Year Plan, focusing on various sub-sectors such as industrial strains and food additives [3]

作为新质生产力的代表，合成生物学、生物制造以及生物产业，近些年，受到来自政产学研用金 各方广泛关注和重点支持，多地政府将合成生物制造产业写进工作报告。 科学家、企业家和投 资家，在产业发展中发挥着重要作用。 融行业智慧、共襄盛举 聚产业力量、擘画未来 SynBio China第三届中国合成生物学"科学家+企业家+投资家"博览会 将于2025年8月1-2日在 苏州国际博览中心B馆 举办（同期举办 第七届CMC-China博览会 ）！ 本次博览会共包含7个子会议： 第三届中国合成生物学"科学家+企业家+投资家"大会 SynBio China合成生物学与食品大健康产业大会 中国蛋白生物制造大会 美之原·合成生物学功能护肤大会 美之注·注射医疗美容产业大会 SynBio China合成生物学产学研对接会 SynBio China合成生物学新锐项目路演 诚邀莅临，共襄盛举 展会名称： Synbio China 第三届中国合成生物学"科学家+企业家+投资家"博览会 展会 时间： 2025年8月1-2日 展会 地点： 苏州国际博览中心·B馆 展会 规模： 20000+ 主办单位： synbio深波 支持单位： Synbio ...